August 3rd 2023
A panel of gynecologic oncologists review the PHAEDRA study and discuss the overall treatment landscape for endometrial cancer.
July 27th 2023
Experts on endometrial cancer review the NRG-GY018 and RUBY clinical trials.
The expert panel switches its focus to endometrial cancer and discusses recent data from clinical trials.
July 20th 2023
Expert gynecologic oncologists react to data from the MIRASOL trial, which studied mirvetuximab in patients with platinum-resistant ovarian cancer.
A panel of experts on ovarian cancer review ongoing trials on maintenance therapies for recurrent ovarian cancer.
July 13th 2023
A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.
Ovarian cancer experts review clinical trial data on the efficacy of later-line therapies in advanced ovarian cancer.
July 6th 2023
A comprehensive overview of recent clinical trial data on PARP inhibitors in the first-line maintenance setting in ovarian cancer presented at ASCO 2023.
An expert panel highlights current unmet needs in the maintenance setting for ovarian cancer.
June 29th 2023
Experts on ovarian cancer discuss germline and somatic testing practices and provide clinical insights on factors that influence treatment decisions.
A panel of expert gynecologic oncologists introduce themselves and review frontline maintenance treatment options in ovarian cancer.
December 8th 2021
Closing out their discussion on the management of cervical cancer, panelists share their excitement for future evolutions in care.
Experts share their experience and thoughts on the use of tisotumab vedotin as the management of metastatic cervical cancer continues to evolve.
December 2nd 2021
Bhavana Pothuri, MD, discusses the challenges of DNA polymerase epsilon mutation testing in endometrial cancer.
Considerations for adverse event management with tisotumab vedotin use in patients with metastatic cervical cancer.
Shared insight on the approval of tisotumab vedotin, an antibody-drug conjugate, in the second-line setting of metastatic cervical cancer.
November 24th 2021
Panelists reflect on the potential for immune checkpoint inhibition to become a frontline option in metastatic cervical cancer, and what that means for the second-line setting.
An overview of second-line immune checkpoint inhibitor use in patients with relapsed or refractory metastatic cervical cancer.
November 18th 2021
Switching its focus to second-line therapy for metastatic cervical cancer, the panel reviews an unmet need of effective therapy in this setting.
Experts take a closer look at the data points from KEYNOTE-826 to consider pembrolizumab’s potential role in metastatic cervical cancer management.